Accepted Manuscript

A randomized controlled cross-over trial evaluating differential responses to antihypertensive drugs (used as mono- or dual-therapy) on the basis of ethnicity: The - comparIsoN oF optimal hypertension RegiMens; part of the ancestry informative markers in HYpertension programme – AIM-HY INFORM trial


PII: S0002-8703(18)30156-X
DOI: doi:10.1016/j.ahj.2018.05.006
Reference: YMHJ 5696

To appear in:

Received date: 31 October 2017
Accepted date: 18 May 2018

Please cite this article as: Omar Mukhtar, Joseph Cherian, John R Cockcroft FESC, David Collier, James M Coulson, Indranil Dasgupta, Luca Faconti, Mark Glover, Anthony M Heagerty, Teck K Khong, Gregory YH Lip, Adrian P Mander, Mellone N Marchong, Una Martin FRCPI, Barry J McDonnell, Carmel M McEniery, Sandosh Padmanabhan, Manish Saxena, Peter J Sever, Julian I Shiel, Julie Wych, Phil J Chowienczyk, Ian B Wilkinson , A randomized controlled cross-over trial evaluating differential responses to antihypertensive drugs (used as mono- or dual-therapy) on the basis of ethnicity: The - comparIsoN oF optimal hypertension RegiMens; part of the ancestry informative markers in HYpertension programme – AIM-HY INFORM trial. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Ymhj(2018), doi:10.1016/j.ahj.2018.05.006

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may
be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
A randomized controlled cross-over trial evaluating differential responses to antihypertensive drugs (used as mono- or dual-therapy) on the basis of ethnicity:
The - comparison of Optimal Hypertension Regimens; part of the Ancestry Informative Markers in Hypertension programme – AIM-HY INFORM trial


Author Affiliations Overleaf

RCT# NCT02847338

Short Title: The AIM-HY INFORM Trial

Word count: 3088

Figures: One

Tables: Four
Author Affiliations


1Dr Omar Mukhtar MRCP, Experimental Medicine & Immunotherapeutics Division, Department of Medicine, University of Cambridge, UK

2Dr Joseph Cheriyan FRCP, Experimental Medicine & Immunotherapeutics Division, Department of Medicine, University of Cambridge, and Cambridge, and Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, UK

3Professor John R Cockcroft FESC, Visiting Professor, Department of Cardiology, Columbia University Medical Center, New York, USA

4Dr David Collier PhD, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, UK

5Dr James M Coulson MD, School of Medicine, Cardiff University, Heath Park Campus, Cardiff, UK

6Dr Indranil Dasgupta FRCP, Departments of Radiology and Renal Medicine, Heart of England Foundation Trust, Birmingham, UK

7Dr Luca Faconti MBBS, Department of Clinical Pharmacology, King’s College London, British Heart Foundation Centre, UK

8Dr Mark Glover PhD, Division of Therapeutics and Molecular Medicine, University of Nottingham, and NIHR Nottingham Biomedical Research Centre, UK

9Professor Anthony M Heagerty FMedSci, Division of Cardiovascular Sciences, University of Manchester, UK

10Dr Teck K Khong FRCP, Blood Pressure Unit, Cardiology Clinical Academic Group, St George’s University of London, Cranmer Terrace, London, UK

11Professor Gregory YH Lip MD, Institute of Cardiovascular Sciences, University of Birmingham, UK

12Dr Adrian P Mander PhD, Medical Research Council Biostatistics Unit, University of Cambridge, UK

13Dr Mellone N Marchong PhD, Office for Translational Research, Cambridge University Health Partners and University of Cambridge, UK

14Professor Una Martin FRCPI, Institute of Clinical Sciences, University of Birmingham, Birmingham, UK

15Dr Barry J McDonnell PhD, Department of Biomedical Sciences, Cardiff Metropolitan University, Cardiff, UK.

16Dr Carmel M McEniery PhD, Experimental Medicine & Immunotherapeutics Division, Department of Medicine, University of Cambridge, UK
Professor Sandosh Padmanabhan FRCP, Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK

Dr Manish Saxena MBBS, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, UK

Professor Peter J Sever FRCP, Faculty of Medicine, National Heart & Lung Institute, Imperial College London, UK

Dr Julian I Shiel MB BCh, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, UK

Dr Julie Wych PhD, Medical Research Council Biostatistics Unit, University of Cambridge, UK

Professor Phil J Chowienczyk FRCP, Department of Clinical Pharmacology, King’s College London, British Heart Foundation Centre, UK

Professor Ian B Wilkinson DM, Experimental Medicine & Immunotherapeutics Division, Department of Medicine, University of Cambridge, and Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, UK
Conflicts of Interest Statement

The authors certify that they have no affiliations with or involvement in any organization or entity with any pecuniary interest or non-pecuniary interest in the subject matter or materials discussed in this manuscript.
Corresponding Author

Dr Omar Mukhtar

Experimental Medicine & Immunotherapeutics Division (EMIT)

Department of Medicine

University of Cambridge

Box 98, Level 3, ACCI

Addenbrooke’s Hospital

Hills Road

Cambridge

CB2 0QQ

Tel: 01223 336806

E-mail: om319@medschl.cam.ac.uk
Abstract

**Background:** Ethnicity, along with a variety of genetic and environmental factors, is thought to influence the efficacy of anti-hypertensive therapies. Current UK guidelines employ a ‘black vs white’ approach; in doing so, they ignore the UK’s largest ethnic minority, Asians from South Asia.

**Study design:** The primary purpose of the AIM-HY INFORM trial is to identify potential differences in response to antihypertensive drugs used as mono- or dual-therapy on the basis of self-defined ethnicity. A multi-center, prospective, open-label, randomized study with two parallel, independent trial arms (mono- and dual-therapy), AIM-HY INFORM plans to enroll a total of 1320 patients from across the UK. Those receiving mono-therapy (n=660) will enter a three-treatment (Amlodipine 10 mg od; Lisinopril 20 mg od; Chlorthalidone 25 mg od), three-period crossover, lasting 24 weeks, whilst those receiving dual-therapy (n=660) will enter a four-treatment (Amlodipine 5 mg od and Lisinopril 20 mg od; Amlodipine 5 mg od and Chlorthalidone 25 mg od; Lisinopril 20 mg od and Chlorthalidone 25 mg od; Amiloride 10 mg od and Chlorthalidone 25 mg od), four-period crossover, lasting 32 weeks. Equal numbers of three ethnic groups (White, Black/Black British, and Asian/Asian British) will ultimately be recruited to each of the trial arms (i.e., 220 participants per ethnic group per arm). Seated, automated, unattended, office, systolic blood pressure measured eight weeks after each treatment period begins will serve as the primary outcome measure.

**Conclusion:** AIM-HY INFORM is a prospective, open-label, randomized trial which aims to evaluate first and second-line anti-hypertensive therapies for multi-ethnic populations.
Introduction

Hypertension is the single biggest contributor to the global burden of disease, a burden that is particularly great in lower and middle-income countries (LMIC). In high income economies, ethnic minorities - often originating from LMICs - also appear to be disproportionately affected, when compared to indigenous populations. Complex interactions between genes and the environment are thought to influence the pathophysiology of essential hypertension, the frequency of hypertension-related complications, and the response to treatment. However, data relating to ethnicity are complicated by the plethora of methods used to define ‘ethnicity’ or ‘race’, and a greater understanding of environmental influences has led to the recognition that data collected in one country, may not be readily applicable to similar ethnic groups in distinct geographical locations.

European guidelines relating to the management of arterial hypertension make no allowance for ethnicity. In contrast, the North American guideline, published by the Joint National Committee in 2014, does, stating, “In the general black population, including those with diabetes, initial antihypertensive treatment should include a thiazide-type diuretic or CCB [calcium channel blocker].” Stratified by age and self-defined ethnicity (SDE), the UK’s National Institute for Health and Care Excellence (NICE) recommends a third approach, with distinct initial mono-therapies recommended for all those aged 55 years and over, as well as for younger black adults when compared to whites. However, the guideline makes no reference to South Asians (i.e. those originating from the Indian sub-continent) - despite the fact that they represent the largest ethnic minority group in the UK at 4.7 million people (52.5 million ‘white British’ citizens being the largest group within a total population of 65.6 million people). Furthermore, the afore-mentioned guidelines fail to extend stratification to combination therapy.

Stratification on the basis of self-defined ethnicity is potentially flawed by virtue of an increasingly ‘ad-mixed’ population, the complex relationship between ethnicity and phenotype and its inherent cohort based approach which fails to account for inter-individual variations.
An alternative method of stratification seeks to utilize ancestry informative markers (AIMs) - genetic polymorphisms occurring with substantially different frequencies across populations from distinct geographical regions. Able to predict geographical ancestry, AIMs may capture the genetic component responsible for variations in drug response amongst ethnically diverse populations more discerningly than SDE.9,10 Concurrent metabolomic profiling of plasma and urine (measurement of low- and intermediate-molecular weight metabolites which reflect the complex inter-play between genetic, physiological, pathophysiological, and/or environmental factors) offers the potential to augment AIMs, with differences between individuals reflecting the entire spectrum of influences, especially diet.11,12

In an effort to address these issues, the AIM-HY INFORM trial intends to compare variations in response to antihypertensive agents amongst three cohorts of the UK population stratified on the basis of SDE, whilst also relating any variations to AIMs and metabolomic profiles. In doing so, we hope to evaluate the validity of current NICE guidance which has SDE at the center of its approach to pharmacotherapy, and to examine whether use of AIMs and/or metabolomic profiling results in the more effective personalization of antihypertensive treatment. Furthermore, the trial will evaluate the efficacy of both mono-therapy and dual-therapy across all three cohorts and try to elucidate potential mechanisms underlying any difference in outcomes achieved by using SDE and AIMs. Thus AIM-HY INFORM will enable clinicians to optimize their choice of anti-hypertensive treatments from current, generic, first- and second-line agents, reducing the attrition of antihypertensive therapies.

**Hypotheses**

We hypothesize that the response to antihypertensive drugs (used either as mono- or dual-therapy) differs by ethnicity.

Our secondary hypothesis relates to the possibility that ancestry informative markers and metabolites, and/or baseline haemodynamic measurements, are able to predict response to antihypertensive therapy.
Methods

Study design and objectives

AIM-HY INFORM is a multi-center, prospective, open-label study with two parallel, independent trial arms (mono- and dual-therapy). Eleven UK sites will enroll a total of 1320 patients. Those receiving mono-therapy (n=660) will enter a three-treatment, three-period crossover, lasting 24 weeks, whilst those receiving dual-therapy (n=660) will enter a four-treatment, four-period crossover, lasting 32 weeks. Equal numbers of all three ethnic groups (White, Black/Black British, and Asian/Asian British) will ultimately be recruited to each of the trial arms (i.e., 220 participants per ethnic group per arm).

The primary objective of the AIM-HY INFORM trial is to determine whether the response to antihypertensive drugs differs on the basis of SDE. Secondary objectives (Table 1) include an evaluation of this response on the basis of AIMs, baseline metabolomics, baseline haemodynamic data, genomics and a more detailed evaluation of SDE (with a family tree extending to three generations, i.e., grandparents). Additionally, the trial aims to determine: 1) the most effective mono- and dual-therapy for hypertension, and any variation(s) by ethnicity, 2) whether metabolomics and haemodynamics differ by ethnicity, and 3) whether previously identified biomarkers (i.e., those derived from other cohorts e.g. the USA) can predict the therapeutic response observed. Further exploratory, tertiary objectives, may be defined.

Study population, treatment assignment and randomization

The inclusion and exclusion criteria are listed in Table II. Hypertensive adults aged between 18 and 65 years are eligible for inclusion, provided that they are able to self-identify with one of the three ethnicities outlined. Treatment-naïve individuals will be confined to the mono-therapy arm. Those who have previously been treated/are being treated with anti-hypertensive agents will be able to enter either arm, provided they are able to under-go a washout of 2-4 weeks; if not, they will be assigned to dual-therapy.
Following allocation to a trial arm, subjects will be randomized to a sequence of drugs (Figure 1) using an online system (https://www.sealedenvelope.com). This requires the participant screening number, initials, date of birth, and self-defined ethnicity, along with the site name, confirmation of eligibility and trial arm allocation. For those receiving mono-therapy, six possible treatment sequences may be generated, as the intervention consists of a three-treatment, three-period crossover; ABC, ACB, BAC, BCA, CAB, and CBA. Where subjects are allocated dual-therapy (a four-treatment, four-period crossover), four possible treatment sequences exist; ABDC, BCAD, CDBA, and DACB. In both instances a Latin square, balanced for first order carryover effects is deployed; the randomization schedule will also aim to have equal numbers of participants in each sequence.

Prescribed in an open-label manner, the treatments allocated to each letter are detailed in Table III. Stable concomitant therapy for unrelated indications is permitted provided it does not have an anti-hypertensive effect; dose modifications for the trial drugs are not permitted. As this is a pragmatic trial of licenced medications, overall adherence will be assessed by urine drug screening for the study medications in a randomly selected subgroup of individuals (n=50). Participants will also be asked to self-report on compliance; where this falls below 75%, subjects may be withdrawn as the discretion of the principal/chief investigator(s).

**Outcome measures**

The primary outcome measure is seated, office, unattended systolic blood pressure measured eight weeks after each treatment period begins. A validated, automated, brachial blood pressure machine – the Omron® HEM-907 - will be used to record three serial measurements.

Secondary and tertiary outcome measures are shown in Table IV. Analysis of potential genetic polymorphisms associated with response to anti-hypertensive treatment will be limited to those polymorphisms previously linked to blood pressure via genome-wide association studies. Preliminary retrospective analyses of randomised controlled trials evaluating the
efficacy of anti-hypertensive drugs suggest that many of these variants are also linked to anti-hypertensive drug response with relatively large effect size; such effects may arise as a result of an overlap between the homeostatic pathways mediating blood pressure control and drug targets. Additionally, genomic variants known to be specifically associated with anti-hypertensive drug response, published prior to the time of analysis, will be evaluated. This will maximise the power of our trial to detect genetic associations, whilst avoiding the limitations of a candidate gene approach. The association with metabolites will be exploratory, utilising a "metabolite-wide" association study (MWAS) approach, whilst also revisiting metabolites that have previously been deemed significant in published metabolite-wide association studies at the time of analysis.

**Sample size calculation**

In order to identify the effect of ethnicity upon response to the various treatment options trialed with 98% power, 200 patients from each of the three ethnic groups, i.e. 600 subjects per trial arm, will be required. This assumes a SD for daytime systolic BP of 8 mmHg, use of a global test of interaction at the 5% significance level and a single interaction of 4 mmHg with others of 0 mmHg. Should the single interaction be 3 mmHg, the power is reduced to 81.3%. However, 4 mmHg is an effect size approximately 50% of that reported for some of the agents to be used in this trial, when studied amongst black and white participants in the USA.

To allow for a 10% dropout rate, the trial will enroll 660 participants per trial arm, with 220 subjects from each of the three ethnic groups. Recruitment for each ethnic group will cease when 220 participants are enrolled, to ensure equal numbers of patients are recruited. Subgroup assessments are not powered as these are exploratory measures.

**Statistical methods**

The two crossover trials will be considered distinct entities for analytical purposes; the results will be interpreted separately, on an intention-to-treat basis. The primary endpoint –
automated, office, systolic blood pressure - will be analyzed using a linear mixed effects model. This endpoint will serve as the dependent variable, participant ID the random effect, with treatment factors, treatment period, ethnic group and treatment by ethnic group the fixed effects. The global test of interaction, at a 5% significance level, will be used to determine whether the treatment effect varies with ethnicity. In the event of a significant global test, the efficacy of individual agents/treatments will be estimated with nominal 95% confidence intervals; the assumptions of the model will be assessed using graphical methods e.g., a Q-Q plot, plots of residual versus fitted values, etc. If any of the assumptions are violated, the dependent variable may be transformed to a normal distribution; if this fails to correct the distributional assumptions, non-parametric methods will be used.

Analysis of secondary and tertiary outcomes will be dependent upon the volume of data acquired; assessments of this (and the appropriate statistical methods) will be determined by the independent chair of the Trial Steering Committee (see below). A detailed statistical analysis plan will be produced before the database is locked and/or before any interim analysis is performed.

**Interim analysis and sample size reassessment**

With limited prior data describing intra-individual standard deviations in SBP, the multilevel nature of the trial design mandates an interim sample size re-estimation. Statistically robust and confined to an analysis of SD in BP, this will be undertaken for each trial arm (mono-therapy and dual-therapy) after approximately 50 participants have completed at least two treatment periods. Given the likelihood that recruitment to the two arms will differ, it is anticipated that the sample size re-estimations are unlikely to occur simultaneously.

Only results of the sample size re-estimation will be communicated to investigators; the details of any treatment effects will not be made available.
Organization and funding

The trial, sponsored by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, is led by the Cambridge Clinical Trials Unit at Cambridge University Hospitals NHS Foundation Trust. Addenbrooke’s Hospital, Cambridge serves as the coordinating center, whilst the Cambridge South (East of England) Research Ethics Committee provided a favourable ethical opinion for the protocol in October 2016.

A Trial Steering Committee (TSC) consisting of experienced clinical investigators provides overall supervision for the trial, ensuring that it is conducted in accordance with the protocol and Good Clinical Practice. Convening at regular intervals and independently chaired (Professor Peter Sever), the committee assumes overall responsibility for participant safety, consideration of new information and reviewing data, as specified in the TSC charter.

Part of the wider AIM-HY consortium, the AIM-HY INFORM trial is funded by the Medical Research Council (MRC) and British Heart Foundation (BHF). The sponsors and funding organizations have no role in the study design, study management, or data interpretation. The investigators (authors) alone are responsible for these aspects of the study, as well as any data analysis, the drafting and editing of manuscripts, and their final contents.

Current status

At present eight investigation centers are actively recruiting patients and it is anticipated that the trial will be completed by mid-late 2020; the results reported approximately six-nine months later. The first patient was consented on 20 February 2017 and randomized on 6 March 2017; as of 15 May 2018, 318 patients had been consented, with 252 randomized. The study has been registered with the website ClinicalTrials.gov (NCT02847338).
Commentary

Ethnicity influences blood pressure status, both at an individual and population level; epidemiological data from the US demonstrate a greater prevalence of hypertension amongst African-Americans, along with poorer blood pressure control amongst this cohort of the population.\textsuperscript{19-22} However, data describing the prevalence of hypertension amongst the UK’s various ethnic groups is inconsistent. Some UK studies describe a greater prevalence of hypertension, and significantly higher mean blood pressure, in both Afro-Caribbean and South Asian populations when compared to the indigenous white population.\textsuperscript{23,24} Other studies have shown significant variations in blood pressure data amongst sub-groups of the South Asian population with some sections of this community reportedly having lower BP readings than white adults; at various times, these differences have been attributed to religion (e.g., Muslim, Sikh, Hindu, etc.), nation of origin (e.g., India, Pakistan, Bangladesh, etc.,) and cultural grouping (e.g., Gujarati, Punjabi, etc.).\textsuperscript{25-27} Furthermore, studies which consider admixed populations are sparse, despite the fact that this cohort of the population is growing in size; over one million people in the UK identify as ‘mixed’, with 0.8% of the English and Welsh population describing themselves as being ‘White-Black Caribbean’, 0.6% ‘White-Asian’, 0.3% ‘White-Black African’ and 0.5% ‘Other Mixed’.\textsuperscript{8}

The pathophysiology of hypertension also appears to vary between ethnic groups. In the UK South Asian population, elevated sympathetic activity, arising from an increased prevalence of central obesity and insulin resistance, is believed to be causally related to blood pressure, whilst ‘low-renin’ hypertension is commonly described amongst black adults, with the resulting salt and water retention a significant determinant of blood pressure status.\textsuperscript{28-32} In contrast, salt-sensitive hypertension is relatively infrequent in white adults.\textsuperscript{31,32} Black patients are also reported to express variants of several genes, most frequently a threonine to methionine substitution, T594M, affecting the renal tubular absorption of sodium and water.\textsuperscript{33} Phenotypically akin to Liddle’s syndrome, this pathophysiological mechanism is primarily mediated via the renal tubular epithelial sodium channel.\textsuperscript{34}
Treatment on the basis of these observations has resulted in the use of diuretics in hypertensive adults with low plasma renin activity, and antagonists of the renin-angiotensin axis (e.g. angiotensin converting enzyme inhibitors (ACEi), angiotensin II receptor blockers (ARBs) or beta-blockers) in individuals with higher plasma renin activity. In addition to this, the parallels to Liddle’s syndrome have led a number of authors to advocate the use of amiloride amongst cohorts of black patients, both in the UK and elsewhere, whilst the elevated sympathetic activity observed amongst South Asians has been used to justify ACEi, ARB and beta-blocker use in this group.

Although data relating to Asians in the North American literature is limited – and where it is available ‘Asian’ frequently equates to ‘Far Eastern’ (Chinese, Japanese, etc.), results from several, large US studies provide some evidence of ethnic variation in response to antihypertensive drugs. In broad terms, greater falls in blood pressure are achieved with thiazide/thiazide-like diuretics in black subjects with hypertension when compared to their white peers; conversely, ACEi are less effective in this cohort. In the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), patients on chlorthalidone achieved better BP control than those receiving lisinopril or amlodipine. Those using lisinopril had a greater risk for stroke (RR: 1.40; 95% CI: 1.17–1.68), combined cardio-vascular disease (RR: 1.19; 95% CI: 1.09–1.30), and heart failure (RR: 1.30; 95% CI: 1.10–1.54) compared with those receiving chlorthalidone; treatment differences which were far more pronounced in African-Americans when compared with whites. Furthermore, the ALLHAT researchers reported a higher risk of stroke in African-American hypertensive patients treated with lisinopril as opposed to amlodipine (RR: 1.51; 95% CI: 1.22–1.86); an association which was not observed in non–African Americans (RR: 1.07; 95% CI: 0.89–1.28). Subsequent meta-analyses reiterate these findings, demonstrating no evident benefit from ACE inhibitors in achieving DBP goals for African-American hypertensive patients. Conversely, ACEi may offer substantial benefits for African-Americans with hypertensive renal disease; in the African-American Study of Kidney Disease and Hypertension (AASK), ramipril slowed renal disease progression in African-Americans irrespective of whether proteinuria was present, more so than amlodipine or metoprolol. However, demographic differences with the UK (e.g., a large
South Asian population, population ‘ad-mixture’, first/second-generation immigrants as opposed to a population resident for two-three centuries, etc.), along with variations in vascular risk, diet and weight, restrict the utility of US data.

The evidence for differential responses to antihypertensive drugs on the basis of ethnicity in the UK is more limited, with an analysis from 203 African, 132 South-Asian and 4368 white participants in the UK arm of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA) perhaps the most robust source of data. This sought to determine whether there were ethnic variations in response to mono-therapy using beta-blockers (atenolol) or calcium channel blockers (amlodipine), and then to add-on therapy with a thiazide diuretic (bendroflumethiazide) or ACEi (perindopril). The degree of blood pressure reduction achieved in black patients receiving atenolol mono-therapy was significantly lower when compared to white patients; South Asian patients achieved an intermediate treatment effect. Amlodipine mono-therapy resulted in similar blood pressure lowering effects across all three ethnic groups, as did the addition of bendroflumethiazide to atenolol. However, the addition of perindopril to amlodipine, resulted in statistically significant BP differences; white patients achieved a further 1.7 mmHg fall in SBP (95% CI: -2.8 to -0.7 mmHg), black patients exhibited a diminished response (SBP change: -0.8 mmHg; 95% CI: -2.5 to +4.2 mmHg) whilst South-Asians demonstrated a greater response (SBP change: -6.2 mmHg; 95% CI -10.2 to -2.2 mmHg).

The AIM-HY INFORM trial aims to optimize first and second-line anti-hypertensive therapies for the multi-ethnic population of the UK. In doing so, it will refine the ‘black vs white’ approach embodied in the current NICE guideline and further codify the treatment of hypertension. The systematic and robust trial data produced will also compare the value of self-defined ethnicity against genetically-defined ancestry and metabolomics, informing future studies in low and middle income countries, where the utilisation of existing, generic, drugs in a resource-efficient manner is imperative.
Acknowledgments

The AIM-HY programme is co-funded by the Medical Research Council and British Heart Foundation (MRC Reference: MR/M016560/1). IBW, CMM and JC acknowledge funding support from the NIHR Cambridge Comprehensive Biomedical Research Centre.
AIM HY INFORM Clinical Trial
Approx. 1320 patients

MONO-THERAPY STUDY
Approx. 660 patients (220 per ethnic group)

A - Amlodipine

B - Lisinopril

C - Chlortalidone

Randomisation (open label) – Monotherapy rotation

Established Hypertension on 1-3 hypertensive medications
AND BP ≥135/85 and/or ≤200/110 mmHg

NO

Minimum 2 week washout

Patient can be washed out
(Office BP <160/100 mmHg)

YES

YES

Ensure consented to Mono-Therapy

Baseline parameters, OMICS*, Physiology, Haemodynamics, ABPM @ CRFA^

NO

NO

Ensure consented to Dual-Therapy

Baseline parameters, OMICS*, Physiology, Haemodynamics, ABPM @ CRFA^

Randomisation (open label) – Dual therapy rotation

Completed Mono-Therapy but fails to achieve target (<135/85 mmHg) – may be eligible for Dual-Therapy

A - Amlodipine
B - Lisinopril
C - Chlortalidone

D - Amlodipine

5 mg + 20 mg

Wk

5 mg + 25 mg

Wk

20 mg + 25 mg

Wk

20 mg + 25 mg

Wk

8 weeks

8 weeks

8 weeks

8 weeks

8 weeks

8 weeks

8 weeks

8 weeks

8 weeks

8 weeks

8 weeks

8 weeks

Figure 1: Trial Flow Chart

*a OMICS = Metabolomic and Genomic analysis
** Dose up-titration in 1 or 2 weeks
^ CRF = Clinical Research Facility
Table I: Trial objectives

**Primary objective**

- To determine whether the response to antihypertensive drugs differs on the basis of self defined ethnicity

**Secondary objectives**

- To determine if the response to antihypertensive drugs differs by:
  - Ancestry Informative Markers
  - Baseline metabolomics
  - Baseline haemodynamics
  - Genomics
  - Detailed SDE (family tree extending to grandparents) of ethnicity background
- To compare detailed SDE with AIMs as a cause for the response to antihypertensive drugs
- To determine the most effective mono- and dual-therapy for hypertension, and whether this varies by ethnicity
- To determine whether metabolomics and haemodynamics differ by ethnicity
- To test whether previously identified biomarkers (derived from other cohorts e.g. US) can predict drug response
Table II: Selection criteria

**Inclusion Criteria**

1. Able to give written informed consent
2. Aged 18 to 65 years
3. Self-defined ethnicity falling into one of three groups:
   - White (White British, White Irish, or any other white background)
   - Black/Black British (Black Caribbean, Black African, or any other black background)
   - Asian/Asian British (Asian Indian, Asian Pakistani, Asian Bangladeshi, or any other South Asian background)
4. Hypertensive as defined by:
   - **Mono-therapy**
     - **Treatment naïve patients:**
       Day-time average SBP $\geq 135$ mmHg or DBP $\geq 85$ mmHg,
       Using ABPM or HBPM (validated device based on an average of 10 readings)
   - **Treated patients:**
     Day-time average SBP $\geq 135$ mmHg or DBP $\geq 85$ mmHg,
     Using ABPM or HBPM (validated device based on an average of 10 readings), if:
     Likely to achieve control on a study drug whilst being willing **and** able to complete 2-4 weeks wash out
   - **Dual-therapy**
     - **Treated (with 1-3 anti-hypertensive agents):**
       Day-time average SBP 135-200 mmHg and/or DBP 85-110 mmHg,
       Using ABPM or HBPM (validated device based on an average of 10 readings)

**Exclusion Criteria**

a. Inability to identify with one of the pre-defined ethnic groups e.g., ad-mixed origin
b. Pregnant or breastfeeding females
c. Known or suspected secondary hypertension
d. Significant sensitivity or contraindications to study medicines
e. Concomitant lithium or variable dose NSAID use
f. A requirement to take any of the study drugs continuously e.g. ACEi and heart failure
g. Clinically significant hepatic impairment
h. Clinically significant kidney impairment
i. Concurrent clinical trial participation (systemically vasoactive medicines or drugs known to interact with the study medicines)
j. Patients deemed unsuitable by the investigator on clinical grounds e.g. patients in atrial fibrillation (AF)
Table III: Selection criteria

**Mono-therapy**

A. 1-2 weeks of Amlodipine 5 mg od followed by 6-7 weeks of Amlodipine 10 mg od

B. 1-2 weeks of Lisinopril 10 mg od followed by 6-7 weeks of Lisinopril 20 mg od

C. Approximately 8 weeks of Chlorthalidone 25 mg od

**Dual-therapy:**

A. Approximately 8 weeks of Amlodipine 5 mg od and Lisinopril 20 mg od

B. Approximately 8 weeks of Amlodipine 5 mg od and Chlorthalidone 25 mg od

C. Approximately 8 weeks of Lisinopril 20 mg od and Chlorthalidone 25 mg od

D. Approximately 8 weeks of Amiloride 10 mg od and Chlorthalidone 25 mg od
Table IV: Outcome Measures

**Primary outcome measure**
- Seated, automated, unattended, office SBP, measured approximately 8 weeks after each treatment

**Secondary outcome measures**
- All participants
  - Seated automated, office DBP
  - Detailed self defined ethnicity
  - Core cardiovascular measurements
    - Body composition assessment to determine lean and fat tissue mass
    - Pulse wave analysis (carotid & femoral arteries) to derive pulse wave velocity, central (aortic) waveforms, and central blood pressure
    - Echocardiography (including left ventricular mass and volume assessments)
    - Dundee (three-minute) step test (baseline only)
- Subgroups
  - ABPM and/or HBPM
  - Optional cardiovascular measurements
    - Heart rate variability
    - Regional arterial diameters
    - CO and SV assessment (using a non-invasive, inert gas re-breathing technique)

**Tertiary outcome measures**
- Haemodynamic and genomic measures
- Baseline demographics comparison
- Urine drug screening (random sub-group sample)
References


